This article is more than 5 years old. Information may no longer be current.

Glaukos, D. Western Therapeutics Institute enter collaboration agreement for ROCK inhibitors

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Glaukos has entered a research and development collaboration agreement with D. Western Therapeutics Institute to develop novel intraocular products for the treatment of glaucoma, the company announced in a press release.

Products will be developed from DWTI’s ROCK inhibitor compound library, while Glaukos will conduct the evaluation and development of those compounds, the release said.

Glaukos will pay DWTI an upfront technology access fee and research support fees, and if one or more candidate compounds are found, Glaukos will hold exclusive rights to develop intracameral and topical products from them.

“We are delighted to enter into this collaboration with D. Western, which has a proven track record of novel drug discovery and is highly regarded in the industry as the preeminent research organization for proprietary ROCK inhibitor compounds,” Thomas Burns, Glaukos president and CEO, said in the release.